Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25929818 | 0.82 | SIRT1 (0.45) | HSD17B10TSHRHPGDCYP3A4ALOX15 | |
| SCHEMBL27851293 | 0.82 | ALOX15 (0.52) | HSD17B10TSHRHPGDCYP3A4ALOX15 | |
| SCHEMBL10771021 | 0.82 | HSD17B10 (0.59) | HSD17B10TSHRHPGDCYP3A4ALOX15 | |
| SCHEMBL10768762 | 0.82 | HSD17B10 (0.59) | HSD17B10TSHRHPGDCYP3A4ALOX15 | |
| SCHEMBL1882971 | 0.80 | HSD17B10 (0.55) | HSD17B10TSHRHPGDCYP3A4ALOX15 | |
| SCHEMBL157575 | 0.80 | CYP3A4 (0.44) | HSD17B10TSHRHPGDCYP3A4ALOX15 | |
| SCHEMBL5589371 | 0.80 | ALOX15 (0.50) | HSD17B10TSHRHPGDCYP3A4ALOX15 | |
| SCHEMBL27557989 | 0.77 | SIRT1 (0.45) | HSD17B10TSHRHPGDCYP3A4ALOX15 | |
| SCHEMBL11434164 | 0.77 | SIRT1 (0.41) | HSD17B10TSHRHPGDCYP3A4ALOX15 | |
| SCHEMBL3132194 | 0.77 | SIRT1 (0.55) | HSD17B10TSHRHPGDCYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283503-B | Method for separating phenol monomer from mixed phenol | 煤炭科学技术研究院有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-116283503-A | Method for separating phenol monomer from mixed phenol | 煤炭科学技术研究院有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113698279-B | Method for separating and extracting 3, 5-xylenol from industrial xylenol | 盐城工学院 | 2022-08-23 | — | — | CN | disclosed |
| CN-113698279-A | Method for separating and extracting 3, 5-xylenol from industrial xylenol | 盐城工学院 | 2021-11-26 | — | — | CN | disclosed |
| US-8138340-B2 | Bicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-20 | — | — | US | disclosed |
| EP-1786814-B1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20090306123-A1 | Bicyclononene derivaties | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
| EP-2029542-A2 | PRIMARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007099509-A2 | PRIMARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-07 | — | — | WO | disclosed |
| EP-1786814-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006131884-A2 | THIAZOLE SUBSTITUTED DIAZABICYCLONONANE OR-NONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-14 | — | — | WO | disclosed |
| US-20060217371-A1 | Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-09-28 | — | — | US | disclosed |
| WO-2006092268-A1 | BICYCLIC FIVE-MEMBERED HETEROARYL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006021401-A2 | BICYLONONENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021402-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-03-02 | — | — | WO | disclosed |
| EP-1622906-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096804-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-4060468-A | TUNGSTEN CONTAINING | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217371-A1 | Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors | REN, ACE, ACE2 | HSD17B10 1559/4885TSHR 2999/4885HPGD 59/4885 |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | HSD17B10 2500/4885TSHR 1974/4885HPGD 490/4885 |
| US-20090306123-A1 | Bicyclononene derivaties | REN, ACE, CYP51A1 | HSD17B10 133/4885TSHR 4450/4885HPGD 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.